Novartis CEO dismisses talk of AstraZeneca purchase

Novartis CEO Daniel Vasella yesterday dismissed talk of the Swiss drugmaker’s interest in purchasing AstraZeneca, Reuters reported. “You shouldn’t expect any major transaction on our side,” Vasella told analysts in a post-results Web cast. “You can forget when you hear about AstraZeneca or other companies.” Novartis, along with GlaxoSmithKline, has been repeatedly mentioned by analysts as a potential bidder for AstraZeneca.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions